Mode
Text Size
Log in / Sign up
Phase 4 N=32 Diagnostic

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure

Pulmonary Heart Disease

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcome: Primary: Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose — -1.9; -1.7 mm Hg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Definity (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Lantheus Medical Imaging
Primary completion
Dec 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose
-1.9; -1.7
SECONDARY
Immunology Panel- Complement 3A (C3A)
-45.80; -38.20
SECONDARY
Immunology Panel- Complement 5A(C5A)
-0.95; 0.78
SECONDARY
Immunology Panel- Interleuken-6
0.31; 0.15
SECONDARY
Immunology Panel- Tryptase
-0.24; -0.01

Summary

The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse effects during Right Heart Catheterization. This research was requested by the FDA.

Eligibility Criteria

Inclusion Criteria

  • Appropriate candidate scheduled to undergo right heart catheterization and measurement of pulmonary artery hemodynamics for clinical reasons
  • Be male or female above the age of 18
  • Female patients who no longer have child-bearing potential
  • Women of Child-Bearing Potential(WOCBP) who:
  • are not pregnant and have been using an adequate and medically approved method of contraception
  • have a negative urine pregnancy test
  • Be able and willing to communicate effectively with study center personnel.

Exclusion Criteria

  • Women who are pregnant or lactating
  • Known hypersensitivity or contraindication to or greater heart block
  • Previous heart transplant
  • Known right-to-left shunt (including atrial septal defect)
  • Severe pulmonary artery hypertension (i.e., > 75 mmHg
  • Current uncontrolled ventricular tachycardia
  • Second-degree or greater heart block
  • Any contraindications for the use of a right heart catheter
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00918866). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search